

## **KOS Diagnostic Lab**

(A Unit of KOS Healthcare)



Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

**NAME** : Mrs. ANU

**AGE/ GENDER** : 68 YRS/FEMALE **PATIENT ID** : 1540045

**COLLECTED BY** :012407060011 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 06/Jul/2024 08:23 AM BARCODE NO. :01512604 **COLLECTION DATE** : 06/Jul/2024 08:51AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 06/Jul/2024 09:56AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

Value Unit **Biological Reference interval** Test Name

## CLINICAL CHEMISTRY/BIOCHEMISTRY

LIPID PROFILE: BASIC

CHOLESTEROL TOTAL: SERUM mg/dL **OPTIMAL:** < 200.0 217.93<sup>H</sup> by CHOLESTEROL OXIDASE PAP

**BORDERLINE HIGH: 200.0 - 239.0** HIGH CHOLESTEROL: > OR = 240.0

> 362.46<sup>H</sup> mg/dL **OPTIMAL: < 150.0**

TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)

**BORDERLINE HIGH: 150.0 - 199.0** HIGH: 200.0 - 499.0

VERY HIGH: > OR = 500.0

HDL CHOLESTEROL (DIRECT): SERUM 42.15 LOW HDL: < 30.0 mg/dL

by SELECTIVE INHIBITION

BORDERLINE HIGH HDL: 30.0 -

60.0  $HIGH\ HDL: > OR = 60.0$ 

103.29 LDL CHOLESTEROL: SERUM OPTIMAL: < 100.0 mg/dL

by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 100.0 - 129.0

BORDERLINE HIGH: 130.0 - 159.0

HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0

NON HDL CHOLESTEROL: SERUM **OPTIMAL: < 130.0** 175.78<sup>H</sup> mg/dL by CALCULATED, SPECTROPHOTOMETRY

ABOVE OPTIMAL: 130.0 - 159.0

**BORDERLINE HIGH: 160.0 - 189.0** 

HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0

VLDL CHOLESTEROL: SERUM 72.49<sup>H</sup> mg/dL 0.00 - 45.00

by CALCULATED, SPECTROPHOTOMETRY **TOTAL LIPIDS: SERUM** 350.00 - 700.00

mg/dL 798.32<sup>H</sup> by CALCULATED, SPECTROPHOTOMETRY

CHOLESTEROL/HDL RATIO: SERUM LOW RISK: 3.30 - 4.40 5.17<sup>H</sup> **RATIO** by CALCULATED, SPECTROPHOTOMETRY **AVERAGE RISK: 4.50 - 7.0** 

**MODERATE RISK: 7.10 - 11.0** 

**HIGH RISK: > 11.0** LDL/HDL RATIO: SERUM 2.45 **RATIO** LOW RISK: 0.50 - 3.0



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





## **KOS Diagnostic Lab**





Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist

Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist

3.00 - 5.00

**NAME** : Mrs. ANU

AGE/ GENDER : 68 YRS/FEMALE **PATIENT ID** : 1540045

**COLLECTED BY** :012407060011 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 06/Jul/2024 08:23 AM BARCODE NO. :01512604 **COLLECTION DATE** : 06/Jul/2024 08:51AM CLIENT CODE. : KOS DIAGNOSTIC LAB REPORTING DATE : 06/Jul/2024 09:56AM

**CLIENT ADDRESS** : 6349/1, NICHOLSON ROAD, AMBALA CANTT

**Test Name** Value Unit **Biological Reference interval** by CALCULATED, SPECTROPHOTOMETRY MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0

**RATIO** TRIGLYCERIDES/HDL RATIO: SERUM 8.6<sup>H</sup> by CALCULATED. SPECTROPHOTOMETRY

INTERPRETATION: 1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

**End Of Report** 



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

0171-2643898, +91 99910 43898 | care@koshealthcare.com | www.koshealthcare.com

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST



KOS Central Lab: 6349/1, Nicholson Road, Ambala Cantt -133 001, Haryana KOS Molecular Lab: IInd Floor, Parry Hotel, Staff Road, Opp. GPO, Ambala Cantt - 133 001, Haryana